In fact, combined blockade of MEK and IGF1R has recently been demonstrated to be a synergistic drug combination across colorectal cancer cell lines59 and reciprocal resistance between IGF1R and EGFR signaling inhibitors has been described in multiple cancer types60. This evidence concerns the gene MAP2K7 and cancer.